Annexon Q3 net loss $32.5M, cash $165.3M; Phase 3 GBS enrollment complete, data H1 2024

Annexon, Inc.

2023-Q3 EPS reported -$1.42

Net loss of $32.5M ($0.43 per share) vs $35.1M ($1.42 per share) in Q3 2022.
Cash, equivalents and investments of $165.3M as of Sep 30, 2023; runway into Q2 2025.
R&D expenses flat at $27.9M; G&A down to $6.9M from $8.2M.
Phase 3 GBS trial enrolled 225 patients; topline pivotal data expected first half 2024.
ANX007 for GA granted EMA PRIME designation; global Phase 3 regulatory discussions ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.